BioSpace News Archive

Starlight Cardiovascular, Inc. announced that it has been awarded a Small Business Innovation Research (SBIR) Phase II grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to advance development of its Ductus Arteriosus Stent System.

Medtronic plc announced Cosmo Pharmaceuticals and NVIDIA plan to integrate NVIDIA’s AI technologies into the GI Genius™ intelligent endoscopy module — the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.

Vascular Dynamics, Inc. (VDI) announced that two-year results from a study assessing its MobiusHD device to treat patients with chronic heart failure were presented today at the Technology and Heart Failure Therapeutics (THT) 2023 meeting in Boston.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States.

Guerbet, a global specialist in contrast agents and solutions for medical imaging, has published its consolidated financial statements for the 2022 fiscal year.

MacroGenics, Inc. (NASDAQ: MGNX) today reported that following the U.S. Food and Drug Administration’s (FDA) approval of Incyte’s Biologics License Application (BLA) for ZYNYZ™ (retifanlimab-dlwr), the Company will receive a $15 million milestone payment from Incyte.

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz™ (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).

POXEL SA announced it will report its 2022 Full year results on March 23, 2023, before market opening.

Leading Medical Center in Israel Leverages YonaLink’s SaaS Platform to Accelerate Innovation and Drive Greater Speed, Quality, and Efficiency in Local and Global Clinical Trial Data Collection

MGC Pharmaceuticals Ltd. announces that its innovative product ArtemiC™ has recently been listed as an over-the-counter drug in the USA on the FDA National Drug Code Database under the code 83278.